Analyzing Kadmon Holdings (NASDAQ:KDMN) & Argos Therapeutics (ARGS)

Kadmon Holdings (NASDAQ: KDMN) and Argos Therapeutics (NASDAQ:ARGS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitabiliy, earnings, risk, valuation, dividends and analyst recommendations.

Valuation and Earnings

This table compares Kadmon Holdings and Argos Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Kadmon Holdings $18.50 million 6.19 -$100.68 million N/A N/A
Argos Therapeutics $904,298.00 10.61 -$48.81 million ($1.48) -0.16

Argos Therapeutics has higher revenue, but lower earnings than Kadmon Holdings.

Profitability

This table compares Kadmon Holdings and Argos Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kadmon Holdings -754.62% N/A -155.28%
Argos Therapeutics -12,391.15% -1,442.99% -76.61%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kadmon Holdings and Argos Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kadmon Holdings 0 2 4 0 2.67
Argos Therapeutics 0 3 0 0 2.00

Kadmon Holdings currently has a consensus target price of $10.88, indicating a potential upside of 392.08%. Argos Therapeutics has a consensus target price of $4.13, indicating a potential upside of 1,681.61%. Given Argos Therapeutics’ higher probable upside, analysts clearly believe Argos Therapeutics is more favorable than Kadmon Holdings.

Insider and Institutional Ownership

40.4% of Argos Therapeutics shares are held by institutional investors. 28.2% of Argos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Argos Therapeutics beats Kadmon Holdings on 6 of the 11 factors compared between the two stocks.

Kadmon Holdings Company Profile

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

What are top analysts saying about Kadmon Holdings Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kadmon Holdings Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit